Hematopoietic Stem Cell TransplantIMPROVE-BMTNCT03886909
Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant
A study testing Exercise and Prehabilitation Education in people with Hematopoietic Stem Cell Transplant and Hematologic Diseases, run by Milton S. Hershey Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to determine whether patients are able to participate in a prehabilitation program (prior to the beginning of treatment) which includes: (1) a home-based exercise program or (2) just a prehabilitation education session. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic Stem Cell Transplant, Hematologic Diseases, Physical Activity
- What is being tested?
- Exercise and Prehabilitation Education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Jun 2019to 13 Apr 2023
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hematological cancer (e.g. Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, etc.)
- Hematological cancer in remission
- Females and males ≥18 years of age
- Fluent in written and spoken English
- Must be able to provide and understand informed consent
- Must have an ECOG score of ≤ 2
Show all 9Show fewer
- Scheduled for an inpatient autologous or allogeneic stem cell transplant at Penn State Cancer Institute
- ≥ 2 weeks until scheduled transplant
- Primary attending physician approval
Who cannot join
- Hematological cancer not in remission
- Evidence in the medical record of an absolute contraindication (e.g. Heart insufficiency > NYHA III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability) for exercise
- Any other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist
- Uncontrolled hypertension
- Receiving non-transplant related chemotherapy and/or radiotherapy
- Not fluent in written and spoken English
- Active infections, hemorrhages, and cytopenias that could place transplant patients at risk for further adverse events, deemed by the exercise interventionist, physician and/or nurse
Trial locations and contacts
1 site in 1 country.
United States1 site
Penn State Cancer Institute
Hershey, Pennsylvania, 17033
About this study
Official title: The Effects of a Prehabilitation Exercise Program in Adults Receiving a Hematopoietic Stem Cell Transplant
The purpose of this study is to determine whether patients are able to participate in a prehabilitation program (prior to the beginning of treatment) which includes: (1) a home-based exercise program or (2) just a prehabilitation education session.
Read the detailed description
Hematopoietic stem cell transplant may have the potential for severe side effects, including functional (reduced aerobic capacity, reduced muscle strength) and psychosocial (e.g. reduced quality of life, increased fatigue) detriments.
Evidence shows that exercise is considered to be an effective treatment approach in hematopoietic stem cell transplant patients during and after treatment with regard to the above mentioned side-effects. Also, prehabilitative exercise in colon and lung cancer patients was shown as feasible and effective. However, no experience exists with regard to prehabilitation exercise in hematopoietic stem cell transplant patients.
- Conditions
- Hematopoietic Stem Cell Transplant, Hematologic Diseases, Physical Activity, Prehabilitation
- Being tested
- Exercise, Prehabilitation Education
- Keywords
- Exercise, Hematopoietic Stem Cell Transplant, Physical function, Quality of Life
- Medical subject headings
- Hematologic Diseases, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseBehavioural
The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
Prehabilitation EducationBehavioural
Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
| Study group | Role | What they receive |
|---|---|---|
| Home-Based Prehabilitation | Active comparator | Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant. Receives: Behavioral: Exercise |
| Prehabilitation Education | Active comparator | Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute. Receives: Behavioral: Prehabilitation Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of the exercise intervention: 50% of included patients actually complete at least one third of the exercise sessions
The exercise intervention will be considered feasible if 50% of included patients actually complete at least one third of the exercise sessions prescribed for 2 weeks or more.
Measured: Through study completion, an average of 18 months
Acceptability of the exercise intervention: more than 50% of the patients approached
The exercise intervention will be considered acceptable if more than 50% of the patients approached agree to receive at least the first exercise session.
Measured: During recruitment
Safety of the exercise intervention: questionnaire
Within the questionnaire we will assess whether musculoskeletal occur (yes/no; ongoing; location; severity (mild-life threatening); daily activities affected). The intervention will be considered as safe if less than 25% of included patients report mild musculoskeletal impairments and less than 5% experienced musculoskeletal injuries (defined as symptoms lasting a week or longer and or requiring the attention of a medical professional).
Measured: Through the study completion, an average of 18 months
Secondary outcomes (13)
Health-related Quality of Life: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0)
QoL will be assessed with the validated 30-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0).
The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Measured: Through study completion, an average of 18 months
Bone Marrow Transplant-related Quality of Life: EORTC QLQ-HDC29
Quality of Life will be assessed with the validated 29-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- High Dose Chemotherapy- 29 Items (EORTC QLQ-HDC29).
The QLQ HDC29 module includes 29 items, consisting of six multi-item scales and eight single-items. For the multi-item scales and single-item scales a high score is equivalent to worse or more symptoms/problems.
Measured: Through study completion, an average of 18 months
Fatigue
Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI) which is a 20-item, multidimensional self-assessment questionnaire.
Respondents use a scale ranging from 1 to 7 to indicate how aptly certain statements regarding fatigue represent their experiences. Higher total scores correspond with more acute levels of fatigue.
Measured: Through study completion, an average of 18 months
Sleep
Sleep quality and sleep problems will be assessed with the validated and frequently used Pittsburgh Sleep Quality Index (PSQI).
In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
Measured: Through study completion, an average of 18 months
Depression
Depressive symptoms will be assessed with the 20-item Center for Epidemiological Studies Depression Scale (CES-D).
Zero for 'Rarely', 1 for 'Some or a little of the time', 2 for 'Occasionally or a moderate amount of time', 3 for 'Most or all of the time'. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.
Measured: Through study completion, an average of 18 months
Short Questionnaire to Assess Health-Enhancing Physical Activity
Physical activity behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Short QUestionnaire to ASsess Health-enhancing Physical Activity (SQUASH).
Household work and activities at work or school were prestructured for intensity. A basic intensity score of 2 and 5 for light and intense activities, respectively. Total minutes of activity are calculated for each question by multiplying frequency (days/week) by duration (min/day). Activity scores for separate questions are calculated by multiplying total minutes of activity by the intensity score. The total activity score is calculated by taking the sum of the activity scores for separate questions. Higher values equals more time spent completing the activity.
Measured: Through study completion, an average of 18 months
Godin Physical Activity Questionnaire
Physical activity behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Godin Physical Activity Questionnaire.
Total weekly leisure activity is calculated in arbitrary units by summing the products of the separate components, as shown in the following formula:
Weekly leisure activity score = (9 × Strenuous) + (5 × Moderate) + (3 × Light) Higher activity score = more active
Measured: Through study completion, an average of 18 months
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) will be used to collect information on severity and interference of symptoms and adverse events.
Measured: Through study completion, an average of 18 months
Body Pain: Brief Pain Inventory- Short form
Bodily pain will be assessed using the Brief Pain Inventory- Short form (BPI-SF).
The BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score is calculated from the four items about pain intensity. Each item is rated from 0, no pain, to 10, pain as bad as you can imagine, and contributes with the same weight to the final score, ranging from 0 to 40. The pain interference score corresponds to the item on pain interference. The seven sub-items are rated from 0, does not interfere, to 10, completely interferes, and contributes with the same weight to the final score, ranging from 0 to 70.
Measured: Through study completion, an average of 18 months
Physical Function: Short Physical Performance Battery
Objectively-measured physical function will be assessed using the Short Physical Performance Battery (SPPB).
The SPPB is an accumulation of balance tests, 4-meter gait speed, and 5-chair stands. Based on the time needed to complete the chair stands, a score is given. A summation of scores from all tests is taken, ranging from 0 -12. A higher score = Higher physical function.
Measured: Through study completion, an average of 18 months
Aerobic Capacity: Six Minute Walk Test
Objectively-measured physical function will be assessed using the Six Minute Walk Test (6MWT).
Distance walked during 6 minutes (measured in meters) is measured. Longer distance = higher aerobic capacity.
Measured: Through study completion, an average of 18 months
Physical Function: Timed-Up-and-Go Test
Objectively-measured physical function will be assessed using the Timed-Up-and-Go test (TUG).
Time taken to stand up from a chair, walk 10 meters around an obstacle, and return to seated position is measured in seconds. Lower time = better physical function.
Measured: Through study completion, an average of 18 months
Fall Risk
Functional balance will be assessed using the Berg Balance Scale.
Scoring: A five-point ordinal scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Score is summation of all items. Highest Total Score = 56 Interpretation: 0-20: Wheelchair bound; 21-40: Walking with assistance; 41-56: Independent
Measured: Through study completion, an average of 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2019
- Study start28 Jun 2019
- Primary completion13 Apr 2023
- Study completion13 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hematopoietic Stem Cell TransplantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shin Mineishi, Milton S. Hershey Medical Center
- Investigators
- Kathryn Schmitz, PhD, Principal investigator, Penn State College of Medicine, Hershey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03886909
- Sponsor's protocol ID
- STUDY00010914
- Acronym
- IMPROVE-BMT
- Status last verified
- Jul 2023
- First submitted
- 12 Mar 2019
- Last updated
- 11 Jul 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Potiaumpai M, Schmitz KH, Mineishi S, Naik S, Wirk B, Rakszawski K, Ehmann WC, Claxton D, Nickolich M, Zemel BS, Zheng H. IMPROVE-BMT: a protocol for a pilot randomised controlled trial of prehabilitation exercise for adult haematopoietic stem cell transplant recipients. BMJ Open. 2023 Jan 18;13(1):e066841. doi: 10.1136/bmjopen-2022-066841.
PubMed 36657760